首页> 美国卫生研究院文献>Diagnostic Pathology >Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos Nigeria four years after change of chloroquine as first-line antimalarial medicine
【2h】

Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos Nigeria four years after change of chloroquine as first-line antimalarial medicine

机译:改变氯喹作为一线抗疟药的四年后尼日利亚拉各斯无疟疾的儿童中恶性疟原虫的抗氯喹单倍型持续存在

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn Nigeria, despite the change in National malaria drug policy to artemisinin combination therapy (ACT) in 2005 due to widespread chloroquine resistance, chloroquine (CQ) is still widely used in the treatment of malaria because it is cheap, affordable and accessible. The use of ACT for the management of uncomplicated malaria is currently being promoted. The employment of genetic markers to track circulating chloroquine-resistant parasites are useful in elucidating likely poor efficacy of chloroquine, especially in settings where it is not recommended for the treatment of uncomplicated falciparum malaria. This study determined the prevalence of pfcrt haplotypes and point mutations in pfmdr1 genes four years after the change in antimalarial treatment policy from CQ to the ACTs in Lagos, a commercial city in South-West, Nigeria.
机译:背景技术在尼日利亚,尽管由于广泛的氯喹耐药性,国家疟疾药物政策于2005年更改为青蒿素联合疗法(ACT),但氯喹(CQ)仍被广泛用于治疗疟疾,因为它价格便宜,负担得起且容易获得。目前正在推广使用ACT来管理简单的疟疾。使用遗传标记物来追踪对氯喹耐药的循环性寄生虫有助于阐明氯喹的不良疗效,特别是在不建议用于治疗单纯性恶性疟疾的地区。这项研究确定了尼日利亚西南部商业城市拉各斯将抗疟疾治疗政策从CQ改为ACTs四年后,pfmdr1基因中pfcrt单倍型和点突变的流行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号